In it’s initial annual report filed in form 10-K, Co-Diagnostics provided important updates on its expansion in the US, Indian and Dominican Republic markets. Co-Diagnostics, a molecular diagnostic Utah corporation, develops and manufactures molecular diagnostic tools and tests for infectious diseases, liquid biopsies and agriculture.
In 2017, Co-Diagnostics formed a joint venture ‘CoSara Diagnostics’ with Synbiotics Private Limited to build a diagnostic test manufacturing facility in India. The company also signed a purchase agreement with MEDCIS Pathlabs Private Limited to purchase diagnostic tests for tuberculosis, Hepatitis B, Hepatitis C, HIV and human papillomavirus. Sales of these tests will commence third quarter 2018 through CoSara Diagnostics.
In addition, the company also discussed it’s new lease on a BSL-2 facility in Utah that will manufacture tests for the US market followed by exports outside the US. Working in collaboration with the Ministries of Health in the Caribbean region, Co-Diagnostics has made strides to tackle outbreaks of Zika virus, tuberculosis, malaria, West Nile virus, chikungunya and dengue with its vector control program.
Co-Diagnostics reported annual revenue of $7662 in 2017 versus none for 2016.